OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Howard Kaufman, MD

home / news-network / howard-kaufman
The Evolution of Immunotherapy in Cancer

EP. 1: The Evolution of Immunotherapy in Cancer

June 21st 2016
Patient Selection for Checkpoint Inhibitor Therapy and Assessing Response

EP. 2: Patient Selection for Checkpoint Inhibitor Therapy and Assessing Response

June 21st 2016
Emerging Checkpoint Inhibitors and Therapeutic Oncolytic Viruses

EP. 3: Emerging Checkpoint Inhibitors and Therapeutic Oncolytic Viruses

June 21st 2016
Adoptive T-Cell Approaches and Tumor Vaccine Strategies

EP. 4: Adoptive T-Cell Approaches and Tumor Vaccine Strategies

June 21st 2016
The Future and the Era of Precision Immunology

EP. 5: The Future and the Era of Precision Immunology

June 21st 2016
Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma

EP. 6: Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma

June 21st 2016
Emerging Agents in the Pipeline for Merkel Cell Carcinoma

EP. 7: Emerging Agents in the Pipeline for Merkel Cell Carcinoma

June 21st 2016
Role of Immunotherapy in Merkel Cell Carcinoma

EP. 8: Role of Immunotherapy in Merkel Cell Carcinoma

June 21st 2016

Latest Conference Coverage

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer

EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact